|
Company Report
|
Abbott Laboratories: PharmaVitae Profile
This analysis examines the historical and forecast performance for Abbott in the prescription pharmaceutical sector. The profile encompasses global company strategy, portfolio and pipeline analysis and assessment of financial performance, with 1-6 year sales forecasts for key drugs. An interactive forecasting and analysis tool provides continually updated quantitative and qualitative information.
|
|
Read more...
|
|
|
Company Report
|
Eli Lilly & Co.: PharmaVitae Profile
This analysis examines the historical and forecast performance for Eli Lilly in the Rx pharmaceutical sector. The profile encompasses global company strategy, portfolio and pipeline analysis and assessment of financial performance, with 1-6 year sales forecasts for key drugs. An interactive forecasting and analysis tool provides continually updated quantitative and qualitative information.
|
|
Read more...
|
|
|
Company Report
|
GlaxoSmithKline plc: PharmaVitae Profile
This analysis examines the historical and forecast performance for GSK in the ethical pharmaceutical sector. The profile encompasses global company strategy, portfolio and pipeline analysis and assessment of financial performance, with 1-6 year sales forecasts for key drugs. An interactive forecasting and analysis tool provides continually updated quantitative and qualitative information.
|
|
Read more...
|
|
|
Company Report
|
Innovative Clinical Trial Design and Management: Trends, success stories and impact upon R&D budgets
Innovative Clinical Trial Design and Management is a report published by Business Insights that explores the major types of adaptive design and their role in dose-finding. The report investigates seamless Phase 2/3 trials and adaptive trials in pharmacogenomics, assesses the logistical implications of adaptive trial implementations and reviews the current regulatory standpoints of the FDA and EMEA.
|
|
Read more...
|
|
|
Company Report
|
Web-assisted relationship- and community-building for the pharmaceutical industry
CRM is a business strategy by which a company seeks to maximize the value of its products by managing the customer relationship, with specific aims to boost customer retention and increase market share, while reducing the costs of sales, marketing and customer fulfillment. CRM is made necessary because of advances in Web-enabled technologies, which have changed the dynamics of sales and marketing.
|
|
Read more...
|
|
|
Company Report
|
OTC Pharmaceuticals: Global Industry Guide
Datamonitor's OTC Pharmaceuticals: Global Industry Guide is an essential resource for top-level data and analysis covering the OTC pharmaceuticals industry. It includes detailed data on market size and segmentation, textual analysis of the key trends and competitive landscape, and profiles of the leading companies. This incisive report provides expert analysis on a global, regional and country basis.
|
|
Read more...
|
|
|
Company Report
|
Benchmarking Patent Expiries - Key Factors Affecting Brand Erosion at Patent Expiry
With declining returns from drug development pipelines, preservation of branded revenues is key for manufacturers. Inevitably though, once the core product patent of a pharmaceutical drug expires, generic companies will launch their own, cheaper versions of the drug, encouraging product switching and eroding the revenues of branded pharmaceuticals.
|
|
Read more...
|
|
|
Company Report
|
Disease Modification in Rheumatoid Arthritis - Competition for the anti-TNF failure
The treatment of Rheumatoid Arthritis (RA) has been rapidly evolving over the last decade. The success of the next wave of novel RA therapies depends on their ability to address the key issue of cost effectiveness, as the patient population for anti-TNF's is reaching a maximum and competition moves to anti-TNF failure patients.
|
|
Read more...
|
|
|
Company Report
|
Hepatocellular Carcinoma - Opportune indication for novel therapies
The close association with hepatitis means that hepatocellular carcinoma (HCC) is common in developing countries where hepatitis B and C infections are endemic. However, the increasing prevalence of hepatitis in the West means that incidence of HCC in the US and Europe is expected to increase significantly over the coming years.
|
|
Read more...
|
|
|
<< Start < Prev 21 22 23 24 25 26 27 Next > End >>
|
| Results 190 - 198 of 238 |
Farmavita.Net Journal 
